BACKGROUND: Existing radiological markers of hematoma expansion (HE) show modest predictive accuracy. We aim to investigate a novel radiological marker that co-localizes findings from non-contrast CT (NCCT) and CT angiography (CTA) to predict HE. METHODS: Consecutive acute intracerebral hemorrhage patients admitted at Foothills Medical Centre in Calgary, Canada, were included. The Black-&-White sign was defined as any visually identified spot sign on CTA co-localized with a hypodensity sign on the corresponding NCCT. The primary outcome was hematoma expansion (⩾6 mL or ⩾33%). Secondary outcomes included absolute (<3, 3-6, 6-12, ⩾12 mL) and relative (0%, <25%, 25%-50%, 50%-75%, or >75%) hematoma growth scales. RESULTS: Two-hundred patients were included, with 50 (25%) experiencing HE. Forty-four (22%) showed the spot sign, 69 (34.5%) the hypodensity sign, and 14 (7%) co-localized both as the Black-&-White sign. Those with the Black-&-White sign had higher proportions of HE (100% vs 19.4%, p < 0.001), greater absolute hematoma growth (23.37 mL (IQR = 15.41-30.27) vs 0 mL (IQR = 0-2.39), p < 0.001) and relative hematoma growth (120% (IQR = 49-192) vs 0% (0-15%), p < 0.001). The Black-&-White sign had a specificity of 100% (95%CI = 97.6%-100%), a positive predictive value of 100% (95%CI = 76.8%-100%), and an overall accuracy of 82% (95%CI = 76%-87.1%). Among the 14 patients with the Black-&-White sign, 13 showed an absolute hematoma growth ⩾12 mL, and 10 experienced a HE exceeding 75% of the initial volume. The inter-rater agreement was excellent (kappa coefficient = 0.84). CONCLUSION: The Black-&-White sign is a robust predictor of hematoma expansion occurrence and severity, yet further validation is needed to confirm these compelling findings.

Department of Biomedical Sciences Humanitas University Pieve Emanuele Milan Italy

Department of Clinical Neurosciences University of Calgary Calgary AB Canada

Department of Community Health Sciences University of Calgary Calgary AB Canada

Department of Medicine Division of Neurology University of Alberta Edmonton AB Canada

Department of Medicine Division of Neurology University of British Columbia Vancouver BC Canada

Department of Medicine Division of Neurology University of Ottawa Ottawa ON Canada

Department of Neurology Kyoto Prefectural University of Medicine Kyoto Japan

Department of Neurology National Institute of Mental Health and Neurosciences Bengaluru India

Department of Neurology University Ostrava Ostrava Czech Republic

Department of Radiology University of Calgary Calgary AB Canada

IRCCS Humanitas Research Hospital Rozzano Milan Italy

Zobrazit více v PubMed

GBD 2019 Stroke Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol 2021; 20: 795–820. PubMed PMC

van Asch CJ, Luitse MJ, Rinkel GJ, et al.. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. Lancet Neurol 2010; 9: 167–176. PubMed

Morotti A, Boulouis G, Dowlatshahi D, et al.. Intracerebral haemorrhage expansion: definitions, predictors, and prevention. Lancet Neurol 2023; 22: 159–171. PubMed

Li Q, Yakhkind A, Alexandrov AW, et al.. Code ICH: a call to action. Stroke 2024; 55: 494–505. PubMed

Gladstone DJ, Aviv RI, Demchuk AM, et al.. Effect of recombinant activated coagulation factor VII on hemorrhage expansion among patients with spot sign-positive acute intracerebral hemorrhage: the SPOTLIGHT and STOP-IT randomized clinical trials. JAMA Neurol 2019; 76: 1493–1501. PubMed PMC

Sprigg N, Flaherty K, Appleton JP, et al.. Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage (TICH-2): an international randomised, placebo-controlled, phase 3 superiority trial. Lancet 2018; 391: 2107–2115. PubMed PMC

Meretoja A, Yassi N, Wu TY, et al.. Tranexamic acid in patients with intracerebral haemorrhage (STOP-AUST): a multicentre, randomised, placebo-controlled, phase 2 trial. Lancet Neurol 2020; 19: 980–987. PubMed

Mayer SA, Brun NC, Begtrup K, et al.. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2008; 358: 2127–2137. PubMed

Liu J, Nie X, Gu H, et al.. Tranexamic acid for acute intracerebral haemorrhage growth based on imaging assessment (TRAIGE): a multicentre, randomised, placebo-controlled trial. Stroke Vasc Neurol 2021; 6: 160–169. PubMed PMC

Al-Ajlan FS, Gladstone DJ, Song D, et al.. Time course of early hematoma expansion in acute spot-sign positive intracerebral hemorrhage: prespecified analysis of the SPOTLIGHT randomized clinical trial. Stroke 2023; 54: 715–721. PubMed

Puy L, Parry-Jones AR, Sandset EC, et al.. Intracerebral haemorrhage. Nat Rev Dis Primers 2023; 9: 14. PubMed

Demchuk AM, Yue P, Zotova E, et al.. Hemostatic efficacy and anti-FXa (factor Xa) reversal with andexanet alfa in intracranial hemorrhage: ANNEXA-4 substudy. Stroke 2021; 52: 2096–2105. PubMed PMC

Morotti A, Boulouis G, Dowlatshahi D, et al.. Standards for detecting, interpreting, and reporting noncontrast computed tomographic markers of intracerebral hemorrhage expansion. Ann Neurol 2019; 86: 480–492. PubMed

Boulouis G, Morotti A, Brouwers HB, et al.. Association between hypodensities detected by computed tomography and hematoma expansion in patients with intracerebral hemorrhage. JAMA Neurol 2016; 73: 961–968. PubMed PMC

Arba F, Rinaldi C, Boulouis G, et al.. Noncontrast computed tomography markers of cerebral hemorrhage expansion: diagnostic accuracy meta-analysis. Int J Stroke 2021: 17474930211061639. DOI: 10.1177/17474930211061639. PubMed DOI

Boulouis G, Morotti A, Charidimou A, et al.. Noncontrast computed tomography markers of intracerebral hemorrhage expansion. Stroke 2017; 48: 1120–1125. PubMed PMC

Barras CD, Tress BM, Christensen S, et al.. Density and shape as CT predictors of intracerebral hemorrhage growth. Stroke 2009; 40: 1325–1331. PubMed

Demchuk AM, Dowlatshahi D, Rodriguez-Luna D, et al.. Prediction of haematoma growth and outcome in patients with intracerebral haemorrhage using the CT-angiography spot sign (PREDICT): a prospective observational study. Lancet Neurol 2012; 11: 307–314. PubMed

Wada R, Aviv RI, Fox AJ, et al.. CT angiography “spot sign” predicts hematoma expansion in acute intracerebral hemorrhage. Stroke 2007; 38: 1257–1262. PubMed

Morotti A, Brouwers HB, Romero JM, et al.. Intensive blood pressure reduction and spot sign in intracerebral hemorrhage: a secondary analysis of a randomized clinical trial. JAMA Neurol 2017; 74: 950–960. PubMed PMC

Morotti A, Boulouis G, Charidimou A, et al.. Integration of computed tomographic angiography spot sign and noncontrast computed tomographic hypodensities to predict hematoma expansion. Stroke 2018; 49: 2067–2073. PubMed PMC

Kosior JC, Idris S, Dowlatshahi D, et al.. Quantomo: validation of a computer-assisted methodology for the volumetric analysis of intracerebral haemorrhage. Int J Stroke 2011; 6: 302–305. PubMed

Morotti A, Li Q, Nawabi J, et al.. Predictors of severe intracerebral hemorrhage expansion. Eur Stroke J 2024: 23969873241247436. DOI: 10.1177/23969873241247436. PubMed DOI PMC

Concha M, Xu L, Horn M, et al.. Predictors of intracranial hemorrhage volume expansion in patients receiving factor Xa inhibitors in ANNEXA-4: time and severity matter most. Stroke Vasc Interv Neurol 2024; 4: e000997.

Yogendrakumar V, Ramsay T, Menon BK, et al.. Hematoma expansion shift analysis to assess acute intracerebral hemorrhage treatments. Neurology 2021; 97: e755–e64. PubMed

Dowlatshahi D, Brouwers HB, Demchuk AM, et al.. Predicting intracerebral hemorrhage growth with the spot sign: the effect of onset-to-scan time. Stroke 2016; 47: 695–700. PubMed PMC

Sporns PB, Schwake M, Schmidt R, et al.. Computed tomographic blend sign is associated with computed tomographic angiography spot sign and predicts secondary neurological deterioration after intracerebral hemorrhage. Stroke 2017; 48: 131–135. PubMed

Wagemans BA, Klinkenberg S, Postma AA. Teaching neuroimages: swirl sign and spot sign in intraparenchymal hematoma. Neurology 2016; 87: e225–e6. PubMed

Delcourt C, Huang Y, Arima H, et al.. Hematoma growth and outcomes in intracerebral hemorrhage: the INTERACT1 study. Neurology 2012; 79: 314–9. PubMed

Dowlatshahi D, Demchuk AM, Flaherty ML, et al.. Defining hematoma expansion in intracerebral hemorrhage: relationship with patient outcomes. Neurology 2011; 76: 1238–1244. PubMed PMC

Rodriguez-Luna D, Coscojuela P, Rodriguez-Villatoro N, et al.. Multiphase CT angiography improves prediction of intracerebral hemorrhage expansion. Radiology 2017; 285: 932–940. PubMed

Schlunk F, Greenberg SM. The pathophysiology of intracerebral hemorrhage formation and expansion. Transl Stroke Res 2015; 6: 257–263. PubMed

Li Q, Zhang G, Xiong X, et al.. Black hole sign: novel imaging marker that predicts hematoma growth in patients with intracerebral hemorrhage. Stroke 2016; 47: 1777–1781. PubMed

Sun SJ, Gao PY, Sui BB, et al.. “Dynamic spot sign” on CT perfusion source images predicts haematoma expansion in acute intracerebral haemorrhage. Eur Radiol 2013; 23: 1846–1854. PubMed

Horn M, Teleg E, Tanaka K, et al.. Timing of spot sign appearance, spot sign volume, and leakage rate among phases of multiphase CTA predict intracerebral hemorrhage growth. AJNR Am J Neuroradiol 2024; 45: 693–700. PubMed PMC

Yogendrakumar V, Mayer SA, Steiner T, et al.. Exploring hematoma expansion shift with recombinant factor VIIa: a pooled analysis of 4 randomized controlled trials. Stroke 2023; 54: 2990–2998. PubMed